Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Otter Pharmaceuticals, Inc.
|
| gptkbp:focus |
prostate cancer therapies
|
| gptkbp:foundedYear |
2004
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tokai Pharmaceuticals, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
galeterone
|
| gptkbp:status |
acquired
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
TKAI
|
| gptkbp:website |
http://www.tokaipharma.com/
|
| gptkbp:bfsParent |
gptkb:NVUS
|
| gptkbp:bfsLayer |
8
|